Response assessment in neuro-oncology
- PMID: 21086192
- DOI: 10.1007/s11912-010-0143-y
Response assessment in neuro-oncology
Abstract
Accuracy and reproducibility in determining response to therapy and tumor progression can be difficult to achieve for nervous system tumors. Current response criteria vary depending on the pathology and have several limitations. Until recently, the most widely used criteria for gliomas were "Macdonald criteria," based on two-dimensional tumor measurements on neuroimaging studies. However, the Response Assessment in Neuro-Oncology (RANO) Working Group has published new recommendations in high-grade gliomas and is working on recommendations for other nervous system tumors. This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma.
Similar articles
-
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15. J Clin Oncol. 2010. PMID: 20231676
-
Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.Chin Clin Oncol. 2017 Aug;6(4):37. doi: 10.21037/cco.2017.06.26. Chin Clin Oncol. 2017. PMID: 28841799 Review.
-
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.Neurosurgery. 2012 Jan;70(1):234-43; discussion 243-4. doi: 10.1227/NEU.0b013e318223f5a7. Neurosurgery. 2012. PMID: 21593697 Review.
-
Radiology: criteria for determining response to treatment and recurrence of high-grade gliomas.Neurosurg Clin N Am. 2012 Apr;23(2):269-76, viii. doi: 10.1016/j.nec.2012.01.006. Epub 2012 Feb 18. Neurosurg Clin N Am. 2012. PMID: 22440870 Review.
-
Neuroradiological response criteria for high-grade gliomas.Clin Neuroradiol. 2011 Nov;21(4):199-205. doi: 10.1007/s00062-011-0080-7. Epub 2011 Jun 17. Clin Neuroradiol. 2011. PMID: 21681688 Review.
Cited by
-
The Longitudinal Imaging Tracker (BrICS-LIT):A Cloud Platform for Monitoring Treatment Response in Glioblastoma Patients.Tomography. 2020 Jun;6(2):93-100. doi: 10.18383/j.tom.2020.00001. Tomography. 2020. PMID: 32548285 Free PMC article.
-
Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.Neuro Oncol. 2012 Feb;14(2):222-9. doi: 10.1093/neuonc/nor200. Epub 2011 Dec 6. Neuro Oncol. 2012. PMID: 22146386 Free PMC article.
-
Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Pigment Cell Melanoma Res. 2016. PMID: 27615400 Free PMC article. Review.
-
Integration of machine learning and mechanistic models accurately predicts variation in cell density of glioblastoma using multiparametric MRI.Sci Rep. 2019 Jul 11;9(1):10063. doi: 10.1038/s41598-019-46296-4. Sci Rep. 2019. PMID: 31296889 Free PMC article.
-
Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.Neuroradiol J. 2019 Aug;32(4):241-249. doi: 10.1177/1971400919847184. Epub 2019 May 8. Neuroradiol J. 2019. PMID: 31066622 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical